- Home
- ANIX vs MOLN Comparison
ANIX vs MOLN Comparison
Compare ANIX & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- MOLN
- Stock Information
- Founded
- ANIX 1982
- MOLN 2004
- Country
- ANIX United States
- MOLN Switzerland
- Employees
- ANIX 5
- MOLN N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- MOLN
- Sector
- ANIX Health Care
- MOLN
- Exchange
- ANIX Nasdaq
- MOLN Nasdaq
- Market Cap
- ANIX 135.3M
- MOLN 154.5M
- IPO Year
- ANIX 1987
- MOLN 2021
- Fundamental
- Price
- ANIX $4.14
- MOLN $4.26
- Analyst Decision
- ANIX Strong Buy
- MOLN Hold
- Analyst Count
- ANIX 3
- MOLN 1
- Target Price
- ANIX $9.00
- MOLN $4.00
- AVG Volume (30 Days)
- ANIX 155.7K
- MOLN 10.6K
- Earning Date
- ANIX 09-10-2025
- MOLN 10-30-2025
- Dividend Yield
- ANIX N/A
- MOLN N/A
- EPS Growth
- ANIX N/A
- MOLN N/A
- EPS
- ANIX N/A
- MOLN N/A
- Revenue
- ANIX N/A
- MOLN N/A
- Revenue This Year
- ANIX N/A
- MOLN N/A
- Revenue Next Year
- ANIX N/A
- MOLN $1,000.00
- P/E Ratio
- ANIX N/A
- MOLN N/A
- Revenue Growth
- ANIX N/A
- MOLN N/A
- 52 Week Low
- ANIX $2.07
- MOLN $3.36
- 52 Week High
- ANIX $4.98
- MOLN $6.15
- Technical
- Relative Strength Index (RSI)
- ANIX 52.15
- MOLN 56.04
- Support Level
- ANIX $4.05
- MOLN $4.07
- Resistance Level
- ANIX $4.60
- MOLN $4.46
- Average True Range (ATR)
- ANIX 0.24
- MOLN 0.36
- MACD
- ANIX -0.02
- MOLN 0.02
- Stochastic Oscillator
- ANIX 48.05
- MOLN 59.84
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.